Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis
Canadian Journal of Cardiology · 2025
DOI: 10.1016/j.cjca.2025.06.068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Cardiology, 2025. Verfasst von Magdalena Kopytek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical R…. Hauptthemen laut MEDLINE: Rivaroxaban, Aortic Valve Stenosis, Aortic Valve, Calcinosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
BACKGROUND: In vitro studies have demonstrated that direct oral anticoagulants (DOACs) downregulate expression of proteins involved in calcification and inflammation. In this hypothesis-testing study we evaluated whether DOAC therapy was associated with decreased valvular calcification in patients with aortic stenosis (AS) who were anticoagulated due to concomitant atrial fibrillation (AF). METHODS: In this case-control study, 72 Caucasian patients with isolated severe AS were compared with 53 individuals with AF concomitant to severe AS who were treated with DOACs for 28.7 ± 13.8 months. Sixteen valves from AS patients on rivaroxaban (20 mg/day, AS-RIVA group) and 20 valves from age- and sex-matched non-anticoagulated patients with AS were subjected to microcomputed tomography (micro-CT) to estimate valvular calcification ex vivo. Calcium volume (CV), surface volume (SV), CV/SV ratio, and trabecular thickness (TbTh) were assessed. Valvular expression of osteopontin, nuclear factor-kappaB (NF-κB), and interleukin-6 (IL-6) were evaluated by immunostaining. RESULTS: Micro-CT showed that patients taking rivaroxaban had a lower CV (-62.7%), lower SV (-46.2%), decreased CV/SV ratio (-35.6%), and maximal TbTh (-21.1%) when compared with patients not taking the drug (P < 0.05 for all). The duration of rivaroxaban use correlated inversely with micro-CT parameters, peak transvalvular velocity, and maximal transvalvular pressure gradient. Decreased valvular expression of osteopontin (-20.4%) and NF-κB (-26%) and 2-fold lower IL-6 fluorescence intensity were observed in the AS-RIVA group compared with the remainder (P < 0.05 for all). Moreover, osteopontin expression was inversely associated with duration of rivaroxaban use and positively with micro-CT parameters. CONCLUSIONS: Long-term rivaroxaban use in AS patients was associated with lower aortic valve leaflet calcification, -as reflected by micro-CT parameters, and osteopontin expression, suggesting a potential impact of rivaroxaban on valvular calcification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland.
- Department of Condensed Matter Physics, Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Krakow, Poland.
- Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, German…
- Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland. E…
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Kopytek, M., Tarasiuk, J., Wroński, S., Mazur, P., Ząbczyk, M., Undas, A., & Natorska, J. (2025). Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2025.06.068
Vancouver
Kopytek M, Tarasiuk J, Wroński S, Mazur P, Ząbczyk M, Undas A, et al. Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis. Canadian Journal of Cardiology. 2025. doi:10.1016/j.cjca.2025.06.068
BibTeX
@article{Kopytek2025,
author = {Kopytek, Magdalena and Tarasiuk, Jacek and Wroński, Sebastian and Mazur, Piotr and Ząbczyk, Michał and Undas, Anetta and Natorska, Joanna},
title = {Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis},
journal = {Canadian Journal of Cardiology},
year = {2025},
doi = {10.1016/j.cjca.2025.06.068}
}
EUVIMED